Daratumumab (Darzalex SC)
Canadian Journal of Health Technologies · 08.05.2026 · 6 (5)
DOI: 10.51731/cjht.2026.1436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 08.05.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses daratumumab (Darzalex SC), 1800 mg/15 mL (120 mg/mL) single-dose vial solution for subcutaneous injection. Indication: Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.
Zitieren
APA
CDA-AMC (2026). Daratumumab (Darzalex SC). Canadian Journal of Health Technologies, 6(5). https://doi.org/10.51731/cjht.2026.1436
Vancouver
CDA-AMC. Daratumumab (Darzalex SC). Canadian Journal of Health Technologies. 2026;6(5). doi:10.51731/cjht.2026.1436
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Daratumumab (Darzalex SC)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {5},
doi = {10.51731/cjht.2026.1436}
}
EUVIMED